Volltext verfügbar nach Anmeldung bzw. im Campus-Netz.
ALX Oncology to Present ALX148 Phase 1 Study at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting
In: Business Wire (English), 2020-05-14
Online
Zeitungsartikel
Zugriff:
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that the Phase 1 study of ALX148 in patients with advanced solid tumors has been selected for presentation in the Poster Discussion Session at the Virtual 2020 ASCO Annual Meeting, May 29 – 31, 2020. [ABSTRACT FROM PUBLISHER]
Titel: |
ALX Oncology to Present ALX148 Phase 1 Study at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting
|
---|---|
Autor/in / Beteiligte Person: | ALX Oncology Holdings Inc. |
Zeitschrift: | Business Wire (English), 2020-05-14 |
Veröffentlichung: | 2020 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|